What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences
Background: The potential value of patient preference studies has been recognized in clinical individual treatment decision-making between clinicians and patients, as well as in upstream drug decision-making. Drug developers, regulators, reimbursement and Health Technology Assessment (HTA) bodies are exploring how the use of patient preference studies could inform drug development, regulatory benefit risk-assessment and reimbursement decisions respectively. Understanding patient preferences may be especially valuable in decisions regarding Non-Small Cell Lung Cancer (NSCLC) treatment options,... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Reihe/Periodikum: | Frontiers in Pharmacology, Vol 12 (2021) |
Verlag/Hrsg.: |
Frontiers Media S.A.
|
Schlagwörter: | patient preferences / drug decision-making / drug development / patient-centered research / lung cancer / benefit-risk assessment / Therapeutics. Pharmacology / RM1-950 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26613464 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3389/fphar.2021.602112 |